Rohto Pharmaceutical, Dynamics Therapeutics Enter into Licensing Agreement for Anti-aging Ingredient Supplamine.Tokyo Tokyo (tō`kēō), city (1990 pop. 8,163,573), capital of Japan and of Tokyo prefecture, E central Honshu, at the head of Tokyo Bay. , Japan, June June: see month. 8, 2006 - (JCN JCN Japan Corporate NewsJCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Rohto Pharmaceutical announced on June 7 that it has concluded a licensing agreement with US venture company Dynamics Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . Under the agreement terms, Rohto will exclusively be able to use Supplamine, an anti-aging ingredient developed by Dynamics Therapeutics, and the related technologies. Supplamine is a substance that reduces the activity of 3-deoxyglucosone (3DG), a hazardous substance related to skin aging. In addition, Rohto will have an equity in Dynamics Therapeutics to reinforce their partnership. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion